Overview

• Pfizer reported adjusted earnings of $0.78 per share in the second quarter, surpassing the FactSet consensus of $0.58.
• Revenue for Q2 rose 10% year over year to $14.65 billion, topping analysts’ $13.56 billion forecast.
• The company lifted its full-year adjusted profit guidance to $2.90–$3.10 per share while maintaining revenue expectations of $61–$64 billion.
• Guidance factors in a one-time $1.35 billion third-quarter charge for the 3SBio licensing deal, current tariffs and possible drug-pricing changes following a presidential letter.
• Pfizer’s multi-year cost realignment programs remain on track to deliver about $7.7 billion in savings by the end of 2027.